Large Molecule Therapeutics
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Zeliang Zheng
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Ryuhei Okada
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Hisataka Kobayashi
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Tadanobu Nagaya
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Junxia Wei
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Qi Zhou
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Fred Lee
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Tapan K. Bera
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Yun Gao
3Selecta Biosciences, Watertown, Massachusetts.
William Kuhlman
3Selecta Biosciences, Watertown, Massachusetts.
Chin-Hsien Tai
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Ira Pastan
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
DOI: 10.1158/1535-7163.MCT-19-0890 Published March 2020

Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
March 2020
Volume 19, Issue 3
Volume 19, Issue 3
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890
Jump to section
Advertisement